Resilience nets another deal, this time with billionaire’s cancer research center
Resilience is having a fun week. Fresh off a $625 million Series D and the launch of a joint venture with MD Anderson, the biomanufacturer Resilience has inked another partnership with an influential cancer center.
Billionaire Napster founder Sean Parker’s Parker Institute for Cancer Immunotherapy (PICI) and Resilience on Wednesday cracked open a five-year strategic alliance to develop and manufacture cancer therapies generated from PICI’s network of immunotherapy research centers.
The deal aims for PICI and Resilience to bring novel cell and gene therapies to market through the creation and incubation of new companies with a commitment of up to $50 million in funding. The deal will leverage technologies from across the PICI Network and have direct access to Resilience’s biomanufacturing capacity and capabilities.
“This strategic alliance is representative of the transformative growth underway at PICI as we take our vision to the next level with new company investments and incubation,” Parker said in a statement.
The agreement will see Resilience also collaborating with PICI investigators on challenges related to biomanufacturing and novel treatment modalities. Resilience will also serve as PICI’s first valued manufacturing partner for complex modalities. It will also work with PICI-affiliated partners.
Resilience and PICI will establish a joint steering committee to approve investments and new company opportunities, monitor and track the progress of alliance portfolio companies, and identify challenge focus areas, among other duties.
This is not PICI’s first foray into forging deals as it has previously worked with biotechs like Xyphos Biosciences to develop a CAR-T therapy. The organization has a slew of partnerships and deals with companies, universities and research organizations since its founding in 2016.
Resilience in the meantime is riding high on its new round of investment to further its mission of becoming the “Foxconn” of biotech, which was intended to be used to build out more deals, potential acquisitions and R&D expansion.